Nathan Connell Reflects on the Impact of COCs on VWD Patients Compared to Healthy People
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared on LinkedIn:
”Navigating a bleeding disorder like von Willebrand Disease (VWD) can be challenging, especially when heavy menstrual bleeding is a major symptom.
Many patients use combination oral contraceptives (COCs) to manage this, but a key question has always been: “Does this affect my diagnosis?”
A recent scoping review and meta-analysis of 27 studies in Haemophilia Journal from Eve Justason, Anna Ishchuk, Benjamin P. Ott, Sophie Gibson, and Paula D. James sought to answer just that.
The researchers found that COC use did not significantly change von Willebrand factor (VWF) or factor VIII (FVIII) levels.
The meta-analysis of VWF% and FVIII% revealed no statistically significant difference between participants with and without COC use (VWF% Estimate: 2.62, p=0.4033; FVIII% Estimate: 2.99, p=0.4552).
These are important data for anyone who is faced with diagnosing VWD.
It provides crucial clarity by validating that COCs do not appear to interfere with the accurate diagnosis of VWD.
This is a vital piece of the puzzle for improving diagnostic certainty and ensuring appropriate management for individuals with bleeding disorders.”
Read the full article in Haemophilia Journal.
Article: Determining the Impact of Combination Oral Contraceptives on Von Willebrand Factor and Factor VIII in Healthy Patients and Patients With Von Willebrand Disease: A Scoping Review and Meta-Analysis
Authors: Eve Justason, Anna M. Ishchuk, Benjamin P. Ott, M. E. Sophie Gibson, Paula D. James
Stay updated on all scientific advances in the field of bleeding disorders with Hemostasis Today.
-
Nov 3, 2025, 08:23The 1st Participant in A New CHECK-NIRS Clinical Study is Enrolled!
-
Nov 3, 2025, 08:15Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial
-
Nov 3, 2025, 07:10Lisa Shea Shares Key Takeaways from NORD Summit 2025
-
Nov 3, 2025, 06:49Darshan Doshi on Results of iMODERN and ILIAS ANOCA Studies Presented at TCT 2025
-
Nov 2, 2025, 14:172019 ESC/EAS Guidelines for the Management of Dyslipidaemias Discussion with Lale Tokgözoğlu and Jeanine Roeters van Lennep
-
Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
-
Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
-
Nov 3, 2025, 04:56Nirupama Ramadas and Erica Sparkenbaugh on Thromboinflammation in SCD
-
Nov 2, 2025, 14:21Claude Franceschi: I Advise You to Understand the Hemodynamic Pathophysiology of Venous Diseases Rather than Blindly Applying Ablation Techniques or Venous Stent Placement
-
Nov 2, 2025, 14:15Krishna Aragam: Why are (DCM) and Heart Failure About Twice as Common in Individuals of Self-Identified Black Race?
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
-
Nov 3, 2025, 09:24Stephen Cornelissen: It’s Not Just About Emergencies — It’s About Everyday Care, Chronic Conditions and Hope
-
Nov 3, 2025, 06:57Maria Elisa Mancuso Reflects on 2025 Annual Congress of the Italian Association of Hemophilia Centres
-
Nov 3, 2025, 05:46Chandra Viswanathan: When Blood Safety Fails, We All Bleed - A Call for Reform and Responsibility
-
Nov 2, 2025, 14:17Anamaria B: Your Mother Still Runs Part of Your DNA
-
Nov 2, 2025, 10:57Paul Bolaji on Launching The First Centralised Nigerian National Stroke Registry